Scleritis: presentations, disease associations and management
- Correspondence to Dr Joanne Sims, Department of Ophthalmology, Auckland District Health Board, Private Bag 92189, Auckland 1142, New Zealand or Auckland Eye, 8 St Marks Road, Remuera, Auckland 1020, New Zealand;
- Received 3 July 2011
- Accepted 4 August 2012
- Published Online First 12 September 2012
Scleritis is a serious inflammatory condition that is often painful, and in severe cases can result in permanent loss of vision. Approximately half the patients affected have no identifiable cause, but 30%–40% have an underlying systemic autoimmune condition. Scleritis may be the initial manifestation of Wegener's granulomatosis or rheumatoid arthritis, and all patients with scleritis require a thorough systemic evaluation.
Scleritis has a variable presentation and disease course, and may be an acute monophasic illness, a relapsing remitting process, or take a chronic course. Treatment options include local therapy with subconjunctival steroid injections for non-necrotising scleritis, and systemic anti-inflammatory or immunosuppressive therapy. Biologic agents have been used with success in some refractory cases. Ocular and systemic morbidity is reduced by timely treatment with immunosuppressant medications.